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Thegrowthandmetastasisofcancersintimatelyinvolvethevasculatureandinparticulartheendothelialcelllayer.Tumoursrequire
new blood vessel formation via angiogenesis to support growth. In addition, inﬂammation, coagulation, and platelet activation
are common signals in the growth and metastasis of tumour cells. The endothelium plays a central role in the homeostatic control
of inﬂammatory cell recruitment, regulating platelet activation and coagulation pathways. PPARα,- β/δ, and -γ are all expressed
in endothelial cells. This review will discuss the roles of PPARs in endothelial cells in relation to angiogenesis, inﬂammation,
coagulation, and platelet control pathways. In particular, we will discuss the recent evidence that supports the hypothesis that
PPARα and PPARγ are antiangiogenic receptors, while PPARβ/δ is proangiogenic.
Copyright © 2008 D. Bishop-Bailey and K. E. Swales. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. IMPORTANCE OF THE ENDOTHELIAL
CELL IN CANCER
Endothelial cells play critical roles in vascular biology, being
both the protective inner lining of vessels and the local site
for delivery of oxygen to all tissues. It has become clear, par-
ticularly from the seminal work of Professor Judah Folkman,
whom this issue is dedicated to, that the endothelium plays a
critical role in the growth and spread of cancer [1–4]. The
growth of tumours, or indeed any tissue growth requires
new blood vessel formation to sustain it. This process of
angiogenesis as a target for modulating cancer growth has
been a major research theme. The critical initial stimulus for
angiogenesis appears to be hypoxia in the growing tumour.
The hypoxia leads to upregulation of hypoxia-induced
transcription factors, for example, hypoxia inducible factor
(HIF)-1α and HIF-2α [5–8], which stimulate the expressions
of genes involved in oxygen homeostasis, and secretion of
proangiogenicmediatorssuchasvascularendothelialgrowth
factor (VEGF) and basic ﬁbroblast growth factor (bFGF) [4,
9, 10]. Although these are key growth factors for endothelial
cell growth and morphogenesis, it is clear that there are
an increasing number of endogenous proangiogenic factors
(PGDF, IL-8, angiopoietin-1, leptin, matrix metallopro-
teinases, thrombin, plasminogen activators) and antiangio-
genic factors (endostatin, angiostatin, thrombospondin-1,
angiopoietin-2, IL-4, IL-12, IL-18, tissue inhibitor of MMPs,
TGF-β,I F N α,- β,a n d- γ)[ 1, 4, 10, 11]. When the cumulative
actions of the proangiogenic mediators outweigh their
antiangiogenic counterparts an “angiogenic switch” occurs
[12]. In particular, VEGF (VEGF-A; VEGF165)i sac e n t r a l
mediator of endothelial cell growth and angiogenesis [13].
Two endothelial VEGF tyrosine kinase receptors have been
identiﬁed: VEGFR-1/Flt-1, and VEGFR-2/KDR/Flk1, with
the latter being the most important in VEGF-induced mito-
genesis and permeability [13]. The lymphatic system and in
particular lymphangiogenesis also contributes signiﬁcantly
to tumour metastasis. Unlike angiogenesis, where VEGF-
(A) and VEGFR1/2 are key regulators, lymphangiogenesis
is regulated by VEGFR-3 and VEGF-C/D isoforms (along
with PROX1, podoplanin, LYVE-1, ephrinB2, and FOXC2)
[14, 15]. Once stimulated by VEGF, the receptors initiate
a signal transduction cascade, activating kinases such as
ERK1/2 and Akt, which phosphorylate and activate further
mediators of endothelial cell proliferation, apoptosis, and
a n g i o g e n e s i s ,s u c ha se N O S[ 16].2 PPAR Research
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Figure 1: The endothelial cell is the interface between the
circulation and underlying tissue, and as such plays an important
homeostatic role both producing and responding to a variety of
pro- and antiangiogenic, inﬂammatory, and coagulation factors.
The balance between these opposing pathways is critical in the
growth, development, spread, and metastasis of tumours.
The endothelium local to the tumour itself also con-
tributes to tumour growth and metastasis via mechanisms
independent of angiogenesis. Of increasing importance is
the role of chronic inﬂammation in tumour progression.
Chronic inﬂammation, in particular the presence of neu-
trophils, macrophages, and mast cells, correlates with poor
prognosis and the angiogenic state of the tumour [17, 18].
Theactivationoftheendotheliumanditssubsequentexpres-
sion of adhesion molecules and chemokines is the interface
for local inﬂammatory cell recruitment and extravasation.
Centraltotheseprocessesareproinﬂammatorytranscription
factors such as NFκB. NFκB regulates many inﬂammatory
processesincludinginduciblecytokine/chemokineandadhe-
sion molecule expressions that are central to inﬂammatory
cell recruitment, as well acting as a potent prosurvival signal
within the cell [19].
In addition to angiogenesis and inﬂammation, cancer
progression and metastasis is also facilitated by circulating
cells and mediators regulated by the endothelium. The
endothelium provides an antithrombotic surface and pro-
duces powerful antiplatelet and anticoagulant mediators
such as prostacyclin, nitric oxide, and tissue- and urokinase-
plasminogen activators [20]. Under physiological condi-
tions, the endothelial surface is antithrombotic. Activated
endothelial cells, however, are able to release prothrom-
botic/procoagulation mediators such as prostaglandin PGE2
[21, 22], plasminogen activator inhibitor (PAI)-1 [23], and
tissue factor [23]. In cancer, thrombocytosis is common
[24], suggesting that the physiological protective system
usually provided by endothelial cells may be dysfunctional
or overpowered by prothrombotic pathways. Driving this
thrombosis may be tumour-derived thrombopoietin, and
tumour- and platelet-derived growth factors and micropar-
ticles [24]. The consequence of activation of the coagulation
cascade in cancer progression can be seen using thrombin
as an example. Thrombin activates tumour cell adhesion
to platelets and endothelial cells, and induces tumour cell
growth, metastasis, and angiogenesis [25].
The movement of tumour cells into and out of the
circulation (or the lymphatics) involves interaction with,
and crossing of, the endothelial barrier. Although tumour
endothelial cells are generally highly permeable (induced by
factors such as VEGF), it is still unlikely that tumour cell
movement is a passive process [26]. Within the circulation,
transit of tumour cells is facilitated by their interactions with
activated platelets [26]. The platelets are believed to act as a
shield, protecting tumour cells from both physical forces and
immune-mediated killing [26].
In summary, along with angiogenesis and lymphan-
giogenesis, endothelial cells regulate tumour progression
not only by directly interacting with tumour cells, but
also by regulating local inﬂammatory cell recruitment, the
coagulation cascade, and platelet activity. When discussing
the actions of PPARs in endothelial cells it is, therefore,
important to consider all these properties.
2. PPARs AND ENDOTHELIAL CELLS
PPARα,P P A R β/δ,a n dP P A R γ are expressed in endothe-
lial cells [27, 28], where they regulate cell proliferation,
angiogenesis, inﬂammation, thrombosis, and coagulation
(Figure 1). PPARα is expressed in human aortic endothelial
cells, carotid artery endothelial cells, and human umbili-
cal vein endothelial cells [27, 29–31]. PPARγ is similarly
expressed in human endothelial cells both in vitro and
in vivo [27, 28, 31, 32], while PPARβ is ubiquitously
e x p r e s s e d .T h er o l eo fP P A R γ has been well characterised
in endothelial cell inﬂammation and angiogenesis [33, 34].
In contrast, the functions of PPARα and PPARβ/δ in
endothelial cells, especially in terms of angiogenesis, are
only just beginning to be understood. Indeed, although the
role of PPARγ will be discussed in this review, since there
is considerable information on PPARγ in cancer [35]a n d
an article on PPARγ regulation of the angiogenic switch in
this review series [36], this manuscript will focus more on
recent observations highlighting novel roles for PPARα and
PPARβ/δ in endothelial cell function and in particular on
the regulation of angiogenesis. The focus of this review is
the endothelial cell, but it is important to note that PPARα,
β/δ,a n dγ expression and activity have been demonstrated
in a variety of cancers, inﬂammatory cells [34], and in
platelets [37–39]. Therefore, any eﬀects of PPAR ligands on
thedevelopment ofcancermaybeinﬂuencedbyresponsesin
these nonendothelial cell types as well.
3. PPARα AND PPARγ: ANTICANCER TARGETS
IN THE ENDOTHELIUM
3.1. PPARαandPPARγ ligands
When discussing the roles of PPARs it is important to note
the types of ligands potentially used in studies. ActivatorsD. Bishop-Bailey and K. E. Swales 3
of PPARα include a variety of eicosanoids, fatty acids, and
synthetic compounds including the clinically used dyslipi-
demic drugs, the ﬁbrates (gemﬁbrozil, fenoﬁbrate, bezaﬁ-
brate, ciproﬁbrate) [40, 41]. Similarly, PPARγ activators also
include a variety of eicosanoids, fatty acids, and synthetic
compounds including the clinically used insulin sensitising
thiazolidinedione drugs (rosiglitazone, pioglitizone, trogliti-
zone (now withdrawn) [40, 41]. (See Figures 2 and 3.)
3.2. PPARαandPPARγ incancer
One early observation regarding PPARα activation by
peroxisome proliferators was the induction of hepatocar-
cinogenesis in rodents; an eﬀect absent in PPARα (−/−)
knockout mice [42, 43]. Although there has been a con-
siderable amount of interest in the ﬁeld, especially as the
PPARα activating ﬁbrates are in clinical use, there is no
evidence that long-term activation of PPARα in nonrodent
species including man is linked to hepatocarcinogenesis
[42, 43].
In extrahepatic tissues, there have been fewer studies
regarding PPARα and cancer. Initially, it was suggested
that PPARα may prevent skin cancer [44, 45]. However,
topical PPARα agonists were only moderately protective
against tumour promotion in mouse skin, despite the
upregulation of PPARα in tumours compared to normal
epidermis [46]. Recent studies have revealed that PPARα
is commonly expressed in tumour cell lines, including
lung, liver, leukaemia, prostate, pancreas, bladder, colon,
glioblastoma, hemangioma, melanoma, ovarian, and breast
[47–49]. PPARα ligands inhibit the growth of colon, breast,
endometrial, and skin cells in vitro [46, 48, 50–52]a n d
human ovarian cancer [53], melanoma, lung carcinoma,
glioblastoma, and ﬁbrosarcoma [48]. PPARα ligands also
decrease tumour development in colon carcinogenesis [52]
and inhibit melanoma cell metastasis in vitro and in vivo
[50, 54].
PPARγ is expressed in prostate, thyroid, colon, breast
and hepatocellular carcinoma, gastric, pancreatic and lung
cancer, neuroblastoma, astrocytoma, and glioma, where the
receptors’ligandsareantiproliferativeandproapoptotic[35].
It is beyond the scope of this review to discuss all the ﬁndings
of PPARγ in cancer, and there are a number of excellent
reviews in the ﬁeld [33, 35, 55, 56] including one on PPARγ
and angiogenesis in this series [36].
The majority of the evidence points towards PPARγ lig-
ands suppressing tumourgenesis, for example, the receptors’
ligands inhibit the growth of xenografts of many of the
aforementioned tumours in vivo [35]. However, in colon
cancer, the beneﬁcial role for PPARγ agonists is controversial
[57]. In the APCmin/+ mouse, PPARγ ligands increased
precancerous polyp formation and the frequency and size
of tumours in the colon [58, 59]. In contrast, heterozygous
loss of PPARγ increases colon cancer incidence in mice [60].
This latter study corresponds with most of the available
data, suggesting that PPARγ has antineoplastic eﬀects in
colon cancer; a point further supported in colon cancer
patient studies by the detection of mutations causing loss
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Figure 2: Endothelial PPARα has predominantly inhibitory actions
onendothelialcellactivation.Themajorityofstudiessofarindicate
that PPARα activation induces (solid line) antiangiogenic factors,
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Figure 3: Endothelial PPARγ has predominantly inhibitory actions
onendothelialcellactivation.Themajorityofstudiessofarindicate
that PPARγ activation inhibits (broken line) proangiogenic factors,
proinﬂammatory pathways, and procoagulant mediator release,
while inducing (solid line) antiangiogenic factors.
of function or impaired ligand binding of PPARγ [61]a n d
polymorphisms of the PPARγ gene [62].
There have been positive results using PPARγ ligands to
treattumoursexperimentallybothinvitroandinvivo,butso
far this has not been successfully translated into a beneﬁcial
anticancer therapy in man. There have been a number of
small scale clinical trials testing PPARγ ligands in cancer in
man with varying success [63]. The most promising results
were from small phase II studies treating prostate cancer
[64] and liposarcoma patients [65] with troglitazone. In
contrast, a phase II study treating liposarcoma patients with
rosiglitazone did not signiﬁcantly improve clinical outcome
[66] and so far no beneﬁcial eﬀects of PPARγ ligands have
been observed in trials for breast or colon cancer patients
[35].4 PPAR Research
3.3. PPARαandPPARγ regulationofangiogenesis
Early studies showed no eﬀect of the selective PPARα ligand
WY-14643 on endothelial cell proliferation [27], however,
recent studies using immortalised human dermal microvas-
cular endothelial cells show that the PPARα ligand fenoﬁ-
brate inhibits endothelial cell proliferation, migration, and
tubeformation(onaﬁbrinmatrix)invitroandangiogenesis
in vivo [67]. Fenoﬁbrate acts by disrupting the formation
of the actin cytoskeleton and inhibits bFGF-induced Akt
activation and cyclooxygenase 2 (COX-2) gene expression
[67]. Similar results were found in a porcine model of
vascular remodelling after coronary artery angioplasty where
fenoﬁbrateincreasedlumensizeandvesselareaandinhibited
constrictive remodelling and inﬂammatory cell inﬁltration
[68]. Importantly, adventitial angiogenesis was signiﬁcantly
reduced by fenoﬁbrate in the injured vessels 3 days after
angioplasty [68].
In contrast to this vascular study, the investigation
of PPARα regulation of tumour angiogenesis has only
just begun. In a recent report, Panigraphy et al. provide
compellingevidenceforPPARαinhibitionoftumourgrowth
by targeting angiogenesis [48]. Similar to previous ﬁndings,
PPARα activation had direct eﬀects on endothelial cells,
inhibiting VEGF-induced endothelial cell migration in vitro
andFGF2inducedcornealangiogenesisinvivo[48].Tumour
cell synthesis of VEGF and FGF2 was also suppressed by
PPARα activation in conjunction with an increased expres-
sion of antiangiogenic thrombospondin-1 (TSP-1) [48]. In
subcutaneously implanted human pancreatic cancer cells
grown in mice, as well as in human prostate cancer, PPARα
expressionwasdetectednotonlyinthetumourcells,butalso
in the new invading microvessels [48]. Systemic treatment of
mice with PPARα ligands inhibited the growth of melanoma,
glioblastoma, and ﬁbrosarcoma tumours implanted in vivo,
which was associated with a reduction in vessel density
and inﬂammation [48]. To dissect the mechanism by which
PPARα suppressed tumour growth (i.e., direct eﬀects on the
tumour and/or angiogenesis), embryonic ﬁbroblasts from
PPARα (−/−) knockout mice were transformed with SV40
large T antigen and H-ras oncogenes then implanted into
wild-type and PPARα−/− mice. The growth of these cells
into tumours could be suppressed by PPARα ligands in
wild-type mice only, indicating that tumour suppression by
PPARα ligands was completely dependent on the expression
of PPARα in the host but not in the tumour cells [48].
Fenoﬁbrate strongly induced the antiangiogenic factors TSP-
1 and endostatin in wild-type, but not PPARα−/− mice,
supporting the role of PPARα as an antiangiogenic regulator
[48]. Angiogenesis and inﬂammation are central processes
through which the tumour interacts with its surroundings to
inﬂuence tumour growth. Although this study does not rule
out an anti-inﬂammatory eﬀect of the PPARα ligands, it is
highly unlikely that the antitumour host-derived eﬀects are
due to suppression of inﬂammation because mice deﬁcient
in PPARα generally exhibit enhanced inﬂammation [64].
TSP-1 is a potent angiogenesis inhibitor that targets
endothelial cells for apoptosis by initiating a signalling
cascade through the CD36 receptor. PPARα directly induces
TSP-1 and can enhance TSP-1 signalling indirectly by
upregulating CD36 in the endothelium. PPARα activation
upregulates CD36 expression in the liver [69] and in
macrophages [70]. Moreover, coadministration of PPARγ
ligands with exogenous TSP-1 or the TSP-1 peptide deriva-
tive ABT510 synergises to suppress angiogenesis and induce
endothelial cell apoptosis [71]. The improvement of the
antiangiogenic eﬃcacy of TSP-1 was attributed to PPARγ-
induced CD36 expression via a PPAR response element in
the CD36 promoter [69, 71].
The vast majority of studies have indicated an antian-
giogenic role for PPARα and PPARγ in a variety of models.
However, it is important to note that the VEGF promoter
containsaPPARresponseelementandPPARαand-γ ligands
can induce VEGF in certain cell types [72–75]. Moreover, in
contrast to the majority of ﬁndings, a recent study suggests
that both PPARα and PPARγ ligands may also have proan-
giogenic properties in vitro in an endothelial/interstitial
cell coculture assay and in a murine corneal angiogenesis
model in vivo [72]. The angiogenesis induced by PPARα and
PPARγ ligands was associated with the induction of VEGF,
accompanied by increased activation of AKT and eNOS (by
phosphorylation) [72]. How the levels of PPARα-o rP P A R γ-
mediated angiogenesis are compared to traditional growth
factor-induced angiogenesis is not known? Indeed, these
results are controversial, as previous corneal angiogenesis
models clearly demonstrate antiangiogenic eﬀects of PPARα
and PPARγ ligands [28, 48, 76].
Multiple mechanisms have been proposed by which
PPARα and PPARγ regulate the changes in pro- and antian-
giogenic factors. Here, we will focus on the central target
for PPAR regulation of angiogenesis, the proangiogenic
VEGF/VEGFR signalling pathway. PPARγ can downregulate
VEGF either directly through a PPAR response element
within the VEGF promoter [77] or by decreasing PGE2,a n
endogenous stimulator of angiogenesis [78]. PPARγ can also
decrease VEGF responses by suppressing transcription of its
receptor VEGFR2, by interacting with and preventing Sp1
binding to DNA [79].
In colorectal cancer cell lines, PPARα also inhibits the
transcription factor AP-1, impairing its binding to response
elements in the VEGF and COX-2 genes and inhibiting
c-jun transactivation activity, thus downregulating VEGF
and COX-2 expression [80]. It is, therefore, clear that the
regulation of angiogenic factors by PPARα and PPARγ may
be determined by cell and cancer type and the experimental
models used. Much more research is required to fully under-
standwhetherPPARactivationwillbepro-orantiangiogenic
in speciﬁc human cancers.
3.4. TheeffectsofPPARαandPPARγ onendothelial
progenitorcells
Endothelial progenitor cells (EPCs) present in periph-
eral blood promote angiogenesis and improve endothelial
function. The research on the eﬀects of PPARs on EPCs
has focused on PPARγ. Despite PPARγ generally being
considered antiangiogenic, the PPARγ ligands rosiglitazone
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progenitor cell (EPC) number and migratory activity [81,
82]. Pioglitazone and rosiglitazone also improve the adhe-
sive capacity of EPCs to ﬁbronectin and collagen [82]
and promote EPC colony formation, [83, 84]. In vitro,
pioglitazone increased EPC proliferation, colony formation,
a n da t t e n u a t e da p o p t o s i s[ 85]. Similarly, in mice pioglita-
zone induced the number and migratory activity of EPCs
while decreasing their apoptosis, resulting in increased in
vivo neoangiogenesis [86]. From these results, it has been
proposed that PPARγ ligands may have a double-edged
role in angiogenesis, with proangiogenic eﬀects on EPCs
at low-systemic concentrations and antiangiogenic eﬀects
at higher local concentrations [86]. Indeed, biphasic eﬀects
of pioglitazone were observed on EPCs in culture, when
the number of EPC colonies and amount of adhesion were
increased by 1μMb u tn o t1 0 μM[ 87]. This higher con-
centration of pioglitazone induced TGF-β1 and its receptor
endogolin,whichsuppressEPCfunction[87].Theseﬁndings
have important clinical implications suggesting that the pro-
/antiangiogenic properties of PPARγ ligands may be largely
dose-driven. Moreover, understanding this mechanism by
which PPARγ may regulate both pro- and antiangiogenic
pathways at least in EPCs may help to explain some of the
contradictions in the studies examining the role of PPARγ in
angiogenesis.
3.5. EffectsofPPARαandPPARγ onendothelial
cellinﬂammation
The role of PPARα in inﬂammation has been studied in
animal models, particularly in wound healing and cardio-
vascular disease models (atherosclerosis and restenosis) [55,
56]. PPARα is a negative regulator of inﬂammation [34]
in inﬂammatory models. Supporting this, PPARα−/− mice
exhibit enhanced inﬂammation [88], although this may be
due in part to deceased β-oxidation and accumulation of
biologically active lipid mediators.
In addition to these experimental models, PPARα ago-
nists decrease the expression of inﬂammatory markers
both in human cells and patients treated with ﬁbrates
[89, 90]. In human endothelial cells in culture, PPARα
ligands inhibit the cytokine/LPS induction of COX-2 [38,
69], ICAM-1 [91], VCAM-1 [29, 31], endothelin-1 [92],
IL-6, and prostaglandin E2 [32, 93]. Similarly, PPARα
ligands repress thrombin-induced expression of endothelin-
1[ 32]. The PPARα ligand fenoﬁbrate, but not the PPARγ
ligand rosiglitazone, also reduces the induction of tissue
factor in human endothelial cells [94], while PAI-1 lev-
els remain unchanged [31]. PPARα inhibits proinﬂam-
matory mediators by interfering with the transactivation
activity of NFκB and AP-1, the main transcription fac-
tors mediating inﬂammatory and growth factor responses.
PPARα via direct protein-protein interactions can bind and
inhibit the actions p65 and c-jun subunits, respectively
[95, 96].
Although the weight of evidence points towards an
anti-inﬂammatory role for PPARα, oxidised lipids that can
activate PPARα have been shown to increase the release of
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Figure 4: Endothelial PPARβ/δ has predominantly proangiogenic
actions on endothelial cells. The majority of studies so far indicate
that PPARβ/δ activation induces (solid line) proangiogenic factors,
while reduces (broken line) antiangiogenic factors. Similar to
PPARα and PPARγ,P P A R β/δ also appears to be anti-inﬂammatory
by reducing proinﬂammatory pathways and potentially anticoagu-
lant by reducing tissue factor release.
neutrophil chemoattractant IL-8 and MCP-1 from endothe-
lial cells [30]. Similarly, PPARα ligands induce COX-2 in
human breast and colon cancer cells [97, 98].
PPARγ, similarly, is a well-established negative regulator
of the inﬂammatory response in vitro and in vivo [34].
PPARγ agonists have been shown to mediate eﬀects on
cell survival, surface-protein expression, and cytokine and
chemokine production. In endothelial cells, PPARγ ligands
can induce apoptosis [27] and decrease inﬂammatory cell
recruitment by inhibiting the production of chemokines IL-
8,MCP-1[30,99],IP-10,Mig,andI-TAC[100]andreducing
ICAM-1expression[101].SimilartoPPAR-α,PP ARγ ligands
repress thrombin-induced expression of endothelin-1 [32].
4. PPARβ/δ
4.1. PPARβ/δ ligands
PPARβ/δ (Figure 4) is almost ubiquitously expressed [102],
althoughcomparedtoPPARαand-γ,lessisknownregarding
its role in the body. However, like PPARα and -γ,i t
appears able to regulate lipid metabolism, cellular prolifer-
ation, and the inﬂammatory response [55, 56]. Activators
of PPARβ/δ include a variety of eicosanoids (the COX
product prostacyclin [40, 41], COX/prostacyclin synthase-
derived endocannabinoid metabolites [103]); fatty acids and
synthetic compounds including GW0742X, GW501516, L-
165,461, and compound F [40, 41].
4.2. PPARβ/δ andcancer
There has recently been an increasing amount of contra-
dictory literature published regarding PPARβ/δ regulation
of tumour cell growth and tumour cell release of VEGF.
PPARβ/δ ligands induce VEGF in bladder cancer [104],
human breast (T47D, MCF7) and prostate (LNCaP, PNT1A)
cancer cell lines, along with its receptor VEGFR1 [105],6 PPAR Research
but not in colon (HT29, HCT116, LS-174T) and hepatoma
(HepG2, HuH7) cell lines [106].
Much of the research into PPARβ/δ in cancer has
focused on gastrointestinal cancer. PPARβ/δ expression is
enhanced in human and rodent colorectal tumours, as well
as preneoplastic colonic mucosa [107, 108]. PPARβ/δ is
transcriptionally regulated by β-catenin/Tcf-4, which can be
suppressed APC. Therefore, in colorectal cancer cells that
commonly carry an APC mutation, PPARβ/δ is upregulated
[108]. Interestingly, PPARβ/δ accumulation was localised to
human colorectal carcinoma cells with a highly malignant
morphology [109], suggesting PPARβ/δ promotes tumouro-
genesis. Supporting this theory, the growth of PPARβ/δ−/−
HCT-116 human colon carcinoma cell xenografts was
reduced compared to wild-type PPARβ/δ expressing cells
[83].
Using animal models, a positive link has been made
between PPARβ/δ and colon cancer development, especially
using the intestinal polyp model, APCmin/+ mice. In this
model, deletion of PPARβ/δ decreases intestinal adenoma
growth and inhibits the tumour-promoting eﬀects of the
PPARβ/δ agonist GW501516 [85, 110]. PPARβ/δ activation
induces VEGF in colon carcinoma cells, promoting cell
survival by activation of Akt signalling [85]. Angiogenesis
was not studied in these experiments, however, for a tumour
to grow greater than 2mm in diameter a functional vessel
network is required [111]. Indeed, the most prominent eﬀect
of PPARβ/δ activation in APCmin/+ mice, observed by Gupta
et al., was a signiﬁcant increase in the number of polyps
greater than 2mm in diameter [110]. Whereas there was
a signiﬁcant decrease in the growth of polyps greater than
2mm in diameter in PPARβ/δ−/− APCmin/+ mice, despite
al a c ko fe ﬀect on overall polyp incidence [112]; indicating
that PPARβ/δ promotes tumour growth via angiogenesis.
In contrast, deletion of PPARβ/δ in APCmin/+ mice
enhanced colon polyp formation in untreated mice and in
mice with chemically induced colon carcinogenesis [113,
114]. The PPARβ/δ ligand GW0742 inhibited chemically
induced colon carcinogenesis in PPARβ/δ wild-type but
not PPARβ/δ−/− mice [115]. The diﬀerences between
these contrasting results have been suggested to be due to
diﬀerences in genetic background, breeding, or the PPARβ/δ
knockout strategy of the APCmin/+ mouse models [116].
However, this would not explain why in human colon and
liver cancer cell lines, PPARβ/δ ligands had no eﬀect on
cell growth, Akt phosphorylation, or VEGF and COX-2
expression in vitro or on these markers in the liver, colon
and colon polyps in mice treated in vivo [106]. The role of
PPARβ/δ in VEGF-mediated tumourgenesis, therefore, still
requires further study and clariﬁcation.
4.3. PPARβ/δ andangiogenesis
Initial reports using prostacyclin as a ligand suggested that
similar to PPARα and PPARγ,P P A R β/δ promoted endothe-
lial cell apoptosis [117], and potentially decreased angiogen-
esis. In contrast, with the development of highly selective
synthetic ligands, there is an increasing evidence to propose
ar o l ef o rP P A R β/δ in regulating endothelial cell survival,
proliferation, and angiogenesis. Indeed, treating endothelial
cells with the selective PPARβ/δ ligand GW501516 induces
proliferation, VEGF receptor (Flt-1; VEGF R1) expression,
and VEGF production [105, 118]. In addition to inducing
proliferation,PPARβ/δ alsoprotectstheendothelialcellfrom
oxidant injury via induction of the antiapoptotic and anti-
inﬂammatory protein 14-3-3α [119].
PPARβ/δ potently induces angiogenesis by human and
murine vascular endothelial cells in tumour extracellular
matrix in vitro and in a murine matrigel plug model in
vivo [118]. The stimulated release of VEGF from human
endothelial cells was a major trigger for morphogenesis,
although mRNA for the matrix metalloproteinase (MMP)-
9, a protease important for cell migration, was also elevated
[118]. In addition to VEGF, genomic and proteomic analysis
of PPARβ/δ−/− endothelial cells isolated from matrigel
plugs identiﬁed a number of additional candidate genes that
may mediate the angiogenic actions of PPARβ/δ. Cdkn1c,
which encodes the cell cycle inhibitor p57Kip2, is induced by
PPARβ/δ [120]. The chloride intracellular channel protein
(CLIC)-4 is decreased in migrating endothelial cells from
PPARβ/δ knockout mice, whereas the expression of cellular
retinol binding protein CRBP1 is increased [121]. CLIC-4
plays an essential role during tubular morphogenesis [122],
while CRBP1 inhibits cell survival pathways by blocking
the Akt signalling pathway [123]. The combination of these
studies indicates that PPARβ/δ may induce endothelial cell
mitogenesis and diﬀerentiation signals, including VEGF, 14-
3-3α, CLIC4, CRBP-1, and p57KIP2, which may combine to
bring about the functional morphogenic changes associated
with the angiogenic switch.
Two recent studies in particular have addressed the
regulation of angiogenesis by PPARβ/δ in matrigel plugs in
PPARβ/δ wild-typeandknockoutmice[120,124].Xenograft
tumours in PPARβ/δ−/− mice exhibited a diminished blood
ﬂow and immature hyperplastic microvascular structures
when compared to wild-type mice. Moreover, the reintro-
duction of PPARβ/δ into the matrigel plugs was able to
rescue the knockout phenotype by triggering microvessel
maturation [120]. In addition, tumour angiogenesis and
growth are markedly inhibited in PPARβ/δ−/− mouse
models of subcutaneous Lewis lung carcinoma and B16
melanoma. PPARβ/δ expression correlated with advanced
pathological tumour stage and increased risk for tumour
recurrence and distant metastasis in pancreatic tumours
from patients who had undergone the “angiogenic switch”
[124]. PPARβ/δ has, therefore, been suggested as a “hub
node”transcriptionfactor,regulatingthetumourangiogenic
switch [124].
4.4. TheeffectsofPPARγβ/δ onendothelial
progenitorcells
Little is known about the eﬀects of PPARβ/δ on EPCs, but
there is one study that shows that PPARβ/δ is a key regulator
of EPC proangiogenic functions. Prostacyclin is a putative
PPARβ/δ ligand and proangiogenic factor, produced by COX
and PGI2 synthase in the endothelium. EPC tube formationD. Bishop-Bailey and K. E. Swales 7
andproliferationareinducedbytheselectivePPARβ/δ ligand
GW510516. EPCs treated with an inhibitor of COX or
COX-1, prostacyclin synthase, or PPARβ/δ speciﬁc siRNA,
exhibitdecreasedcellproliferationandtubeformation[125].
Thus the proangiogenic eﬀects of human EPCs appear in
part dependent on the biosynthesis of prostacyclin and the
subsequent activation of PPARβ/δ.
4.5. TheeffectofPPARβ/δ onendothelial
cellinﬂammation
Little is known regarding the role of PPARβ/δ in endothelial
cell inﬂammation and mediator secretion. PPARβ/δ ligands,
similar to PPARα and PPARγ ligands, inhibit cytokine-
stimulated upregulation of adhesion molecules ICAM-1,
VCAM-1, and e-selectin and NFκB translocation [126, 127].
These anti-inﬂammatory eﬀects of PPARβ/δ in endothelial
cells occur when the complex between PPARβ/δ and the
transcriptional repressor BCL6 is removed by ligand acti-
vation, identical to the mechanism identiﬁed in monocytes
[128]. PPARβ/δ and BCL6 are then free to act on PPARβ/δ
targets(includingSODandcatalase)andBCL6targetswhich
importantly include the repression of NFκB. In addition to
anti-inﬂammatory eﬀects, endogenous PPARβ/δ ligands are
continuously produced in endothelial cells to suppress the
release of tissue factor, the primary initiator of coagulation
[103].
5. PPAR THERAPY FOR CANCER
The PPARs have pleiotrophic actions on nonvascular and
vascular cells. PPARα and PPARγ ligands (although there
are well-detailed current concerns for rosiglitazone) are in
clinical use, are considered safe, and have high tolerability
with chronic use. There is considerable evidence that PPARγ
and increasing evidence that PPARα are vascular protective
and reduce angiogenesis. Unfortunately, as yet, there is a
little clinical evidence to support these actions, apart from
the promising results with the PPARγ ligand troglitazone
in liposarcoma and prostate cancer previously mentioned
[64, 65]. Clinically, PPARα and γ ligands do not appear
to be strong antiangiogenic drugs. However, since PPARα
and PPARγ ligands are in clinical use and lack severe
side eﬀects, the potential for their use to complement
or augment current and new therapies to treat a variety
of cancers is currently being tested in small scale trials.
For example, a phase II trial combining anti-inﬂammatory
and angiostatic therapy (PPARγ ligand pioglitazone and
COX-2 inhibitor, rofecoxib) with metronomic low-dose
chemotherapy (trofosamide)found that the progression-free
survival rates of advanced melanoma patients were longer
with the combination treatment than with metronomic
chemotherapy alone [129]. This combination therapy was
also successful in achieving disease stabilization or remission
in patients with advanced progressive malignant vascular
tumours [130] and partial remission in a single patient
with endemic Kaposi sarcoma [131]. However, a similar
phaseIIstudyonhigh-gradegliomapatients,showeddisease
stabilisation in only 4 out of 14 patients, suggesting that
this combined therapy may only be suitable for a subset of
patients [132]. The COX-2 inhibitor rofecoxib was included
in the trial because COX-2 plays a role in endothelial tube
formation,pericyterecruitment,andendothelialcellsurvival
during early angiogenesis [133]. As PPARα and γ ligands
have been shown to inhibit COX-2 induction in endothelial
cells, it would be interesting to test the combined eﬀects of
PPARαor −γ ligandswithmetronomicchemotherapyalone.
In contrast to PPARα and PPARγ, there is increasing
evidence that PPARβ/δ is proangiogenic and an important
transcription factor in the angiogenic switch. PPARβ/δ has
an interesting activity proﬁle in that like the other PPARs
it also appears to have anti-inﬂammatory properties. As
PPARβ/δ is considered a target to treat dyslipidaemia, its
proangiogenic properties should, therefore, be considered
in the long-term use of PPARβ/δ ligands to treat chronic
metabolic diseases. The development of selective antagonists
for PPARβ/δ oﬀers great potential for cancer treatment.
One such antagonist has recently been identiﬁed, GSK0660,
which can compete with agonist in a cellular context and by
itself exhibits inverse agonist activity [134]. This antagonist
appears to act by promoting PPARβ/δ-mediated repression
of gene expression. Unfortunately, this compound lacks
in vivo bioavailability, but will be a valuable tool for
elucidating the role of PPARβ/δ in cancer and angiogenesis
in vitro and a basis for further development of a selective
bioavailable PPARβ/δ antagonist [134]. Selective modulators
of PPARβ/δ, which maintain the beneﬁcial metabolic (and
anti-inﬂammatory) eﬀects while exerting no proangiogenic
eﬀects would also be beneﬁcial. Interestingly, there is a newly
developed PPAR-α agonist (R)-K-13675, which inhibits the
secretion of inﬂammatory markers without aﬀecting cell
proliferation or endothelial tube formation [135], which
suggests that selective modulators for the other PPARs may
soon be available.
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